Cargando…

Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan

INTRODUCTION: The BNT162b2 and mRNA-1273 COVID-19 vaccines are the main vaccines that have been used for mass vaccination in Japan. Information on adverse reactions to COVID-19 vaccines in the Japanese population is limited. METHODS: We conducted an online survey on self-reported adverse reactions i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitagawa, Hiroki, Kaiki, Yuki, Sugiyama, Aya, Nagashima, Shintaro, Kurisu, Akemi, Nomura, Toshihito, Omori, Keitaro, Akita, Tomoyuki, Shigemoto, Norifumi, Tanaka, Junko, Ohge, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747950/
https://www.ncbi.nlm.nih.gov/pubmed/35058126
http://dx.doi.org/10.1016/j.jiac.2021.12.034
_version_ 1784630955657396224
author Kitagawa, Hiroki
Kaiki, Yuki
Sugiyama, Aya
Nagashima, Shintaro
Kurisu, Akemi
Nomura, Toshihito
Omori, Keitaro
Akita, Tomoyuki
Shigemoto, Norifumi
Tanaka, Junko
Ohge, Hiroki
author_facet Kitagawa, Hiroki
Kaiki, Yuki
Sugiyama, Aya
Nagashima, Shintaro
Kurisu, Akemi
Nomura, Toshihito
Omori, Keitaro
Akita, Tomoyuki
Shigemoto, Norifumi
Tanaka, Junko
Ohge, Hiroki
author_sort Kitagawa, Hiroki
collection PubMed
description INTRODUCTION: The BNT162b2 and mRNA-1273 COVID-19 vaccines are the main vaccines that have been used for mass vaccination in Japan. Information on adverse reactions to COVID-19 vaccines in the Japanese population is limited. METHODS: We conducted an online survey on self-reported adverse reactions in individuals who had received two doses of the BNT162b2 or mRNA-1273 vaccine. The incidence of adverse events after each dose of vaccine was investigated. Propensity score matching was used to compare the incidence of adverse reactions after the second dose of the BNT162b2 and mRNA-1273 vaccines. RESULTS: After the first and second doses of the BNT162b2 vaccine, and the first and second doses of the mRNA-1273 vaccine, 890, 853, 6401, and 3965 individuals, respectively, provided complete responses. Systemic reactions, including fever, fatigue, headache, muscle/joint pain, and nausea were significantly more common in females, individuals aged <50 years, and after the second dose. The incidence of injection site pain did not differ significantly according to the dose. The incidence of delayed injection site reactions after the first dose of mRNA-1273 vaccine was 3.9% and 0.8% among females and males, respectively, and 10.6% among females aged 40–69 years. Local and systemic reactions after the second dose, including fever, fatigue, headache, muscle/joint pain, nausea, and skin rash were more common in individuals who had received the mRNA-1273 vaccine. CONCLUSIONS: Adverse reactions were more frequently reported in females, younger individuals, and after the mRNA-1273 vaccine.
format Online
Article
Text
id pubmed-8747950
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-87479502022-01-11 Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan Kitagawa, Hiroki Kaiki, Yuki Sugiyama, Aya Nagashima, Shintaro Kurisu, Akemi Nomura, Toshihito Omori, Keitaro Akita, Tomoyuki Shigemoto, Norifumi Tanaka, Junko Ohge, Hiroki J Infect Chemother Original Article INTRODUCTION: The BNT162b2 and mRNA-1273 COVID-19 vaccines are the main vaccines that have been used for mass vaccination in Japan. Information on adverse reactions to COVID-19 vaccines in the Japanese population is limited. METHODS: We conducted an online survey on self-reported adverse reactions in individuals who had received two doses of the BNT162b2 or mRNA-1273 vaccine. The incidence of adverse events after each dose of vaccine was investigated. Propensity score matching was used to compare the incidence of adverse reactions after the second dose of the BNT162b2 and mRNA-1273 vaccines. RESULTS: After the first and second doses of the BNT162b2 vaccine, and the first and second doses of the mRNA-1273 vaccine, 890, 853, 6401, and 3965 individuals, respectively, provided complete responses. Systemic reactions, including fever, fatigue, headache, muscle/joint pain, and nausea were significantly more common in females, individuals aged <50 years, and after the second dose. The incidence of injection site pain did not differ significantly according to the dose. The incidence of delayed injection site reactions after the first dose of mRNA-1273 vaccine was 3.9% and 0.8% among females and males, respectively, and 10.6% among females aged 40–69 years. Local and systemic reactions after the second dose, including fever, fatigue, headache, muscle/joint pain, nausea, and skin rash were more common in individuals who had received the mRNA-1273 vaccine. CONCLUSIONS: Adverse reactions were more frequently reported in females, younger individuals, and after the mRNA-1273 vaccine. Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. 2022-04 2022-01-11 /pmc/articles/PMC8747950/ /pubmed/35058126 http://dx.doi.org/10.1016/j.jiac.2021.12.034 Text en © 2022 Japanese Society of Chemotherapy and The Japanese Association for Infectious Diseases. Published by Elsevier Ltd. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Original Article
Kitagawa, Hiroki
Kaiki, Yuki
Sugiyama, Aya
Nagashima, Shintaro
Kurisu, Akemi
Nomura, Toshihito
Omori, Keitaro
Akita, Tomoyuki
Shigemoto, Norifumi
Tanaka, Junko
Ohge, Hiroki
Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
title Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
title_full Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
title_fullStr Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
title_full_unstemmed Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
title_short Adverse reactions to the BNT162b2 and mRNA-1273 mRNA COVID-19 vaccines in Japan
title_sort adverse reactions to the bnt162b2 and mrna-1273 mrna covid-19 vaccines in japan
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8747950/
https://www.ncbi.nlm.nih.gov/pubmed/35058126
http://dx.doi.org/10.1016/j.jiac.2021.12.034
work_keys_str_mv AT kitagawahiroki adversereactionstothebnt162b2andmrna1273mrnacovid19vaccinesinjapan
AT kaikiyuki adversereactionstothebnt162b2andmrna1273mrnacovid19vaccinesinjapan
AT sugiyamaaya adversereactionstothebnt162b2andmrna1273mrnacovid19vaccinesinjapan
AT nagashimashintaro adversereactionstothebnt162b2andmrna1273mrnacovid19vaccinesinjapan
AT kurisuakemi adversereactionstothebnt162b2andmrna1273mrnacovid19vaccinesinjapan
AT nomuratoshihito adversereactionstothebnt162b2andmrna1273mrnacovid19vaccinesinjapan
AT omorikeitaro adversereactionstothebnt162b2andmrna1273mrnacovid19vaccinesinjapan
AT akitatomoyuki adversereactionstothebnt162b2andmrna1273mrnacovid19vaccinesinjapan
AT shigemotonorifumi adversereactionstothebnt162b2andmrna1273mrnacovid19vaccinesinjapan
AT tanakajunko adversereactionstothebnt162b2andmrna1273mrnacovid19vaccinesinjapan
AT ohgehiroki adversereactionstothebnt162b2andmrna1273mrnacovid19vaccinesinjapan